Compare GSK plc (GSK) vs JetBlue Airways Corporation (JBLU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs JetBlue Airways Corporation — how do they compare? GSK plc trades at $52.85 (market cap $101.34B), while JetBlue Airways Corporation trades at $5.63 (market cap $2.07B). The key difference: GSK plc is far larger — about 49× JetBlue Airways Corporation's market cap, and GSK plc pays a 3.49% dividend while JetBlue Airways Corporation pays none. Which is the better fit depends on your goals.
| GSK | JBLU | |
|---|---|---|
Market Cap | $101.34B | $2.07B |
Sector | Health | Industrials |
52-Week High | $61.18 | $6.46 |
52-Week Low | $36.20 | $4.03 |
Enterprise Value | $121.95B | $9.24B |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
JetBlue (JBLU) trades at $5.525, up 3.66% today, but remains below the consensus price target of $5.12. The stock shows a neutral technical signal with mixed moving averages and oscillators. Fundamentally, JBLU faces challenges with negative net income margins and ROE, though it maintains a low P/S ratio of 0.22. Recent news highlights expansion at Fort Lauderdale and a new payment partnership, but earnings misses in Q4 2025 and Q1 2026 underscore ongoing profitability struggles amid high debt levels.
The outlook for JBLU is cautious due to persistent losses and elevated leverage, offset by cost initiatives and strategic growth. Risks include fuel price volatility and competitive pressures, while analyst sentiment is mixed with a majority hold rating. Investors should weigh turnaround potential against financial headwinds in a cyclical industry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →
